Abstract 578: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of prostate cancer
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Denis Beckford, Sumit Mukherjee, Debbie Lewis, Jason Li, Dina Yang, Karina Peregrina, Amanda Chin, Le-Cun Xu, Monideepa Roy, Adeela Kamal
Institution: Actinium Pharmaceuticals (United States)
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409691516